A Comparison of Exenatide and Insulin Glargine

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

October 31, 2016

Conditions
Type 2 Diabetes
Interventions
DRUG

exenatide

5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.

DRUG

Insulin glargine

≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.

Trial Locations (1)

210008

at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT02325960 - A Comparison of Exenatide and Insulin Glargine | Biotech Hunter | Biotech Hunter